EVP-6124 (0.3 mg/day)

DRUG2 trials

Sponsors

FORUM Pharmaceuticals Inc

Conditions

Alzheimer's DiseaseCentral Nervous System DiseasesSchizoaffective DisorderSchizophrenia

Phase 1

Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's Disease

CompletedNCT00766363

FORUM Pharmaceuticals IncAlzheimer's Disease, Central Nervous System Diseases

Start: 2008-10-31End: 2009-03-31Updated: 2012-04-20

Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Schizophrenia

CompletedNCT01556763

FORUM Pharmaceuticals IncCentral Nervous System Diseases, Schizoaffective Disorder, Schizophrenia

Start: 2008-04-30End: 2008-08-31Updated: 2012-06-21

Related Papers

Normalizing effects of EVP-6124, an α-7 nicotinic partial agonist, on event-related potentials and cognition: a proof of concept, randomized trial in patients with schizophrenia.

2014-01-01107 citations